GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Cash Flow from Investing

Evofem Biosciences (Evofem Biosciences) Cash Flow from Investing : $-0.02 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Evofem Biosciences spent $0.01 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Evofem Biosciences spent $0.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Evofem Biosciences Cash Flow from Investing Historical Data

The historical data trend for Evofem Biosciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Cash Flow from Investing Chart

Evofem Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.12 6.23 -2.69 -0.34 -

Evofem Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.01

Evofem Biosciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Evofem Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Evofem Biosciences's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evofem Biosciences  (OTCPK:EVFM) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Evofem Biosciences's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.01 Mil. It means Evofem Biosciences spent $0.01 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Evofem Biosciences's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Evofem Biosciences gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Evofem Biosciences's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Evofem Biosciences spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Evofem Biosciences's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Evofem Biosciences gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Evofem Biosciences's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Evofem Biosciences spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Evofem Biosciences's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Evofem Biosciences gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Evofem Biosciences's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Evofem Biosciences paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Evofem Biosciences's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Evofem Biosciences paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Evofem Biosciences's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Evofem Biosciences paid $0.00 Mil for other investing activities.


Evofem Biosciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Evofem Biosciences (Evofem Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Executives
Yan Zhang officer: Chief Financial Officer 6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar director, 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip director 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca officer: Chief Commercial Officer 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier director, officer: Chief Executive Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: General Counsel and Secretary 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File officer: Chief Financial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans officer: Chief Commercial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd. 10 percent owner 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd 10 percent owner 65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp 10 percent owner 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell officer: Chief Medical Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130